Alternative lengthening of telomeres confers favorable prognosis in chondrosarcomas
Open Access
- 12 May 2025
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-11
Abstract
Cancer cells achieve replicative immortality through telomere maintenance mechanisms (TMMs), primarily via telomerase activation or alternative lengthening of telomeres (ALT). Sarcomas frequently employ the ALT pathway, which traditionally correlates with adverse clinical outcomes. However, chondrosarcomas represent a unique context where the role and prognostic significance of ALT remain largely unexplored. We performed comprehensive analyses of single-cell RNA-sequencing data from patients with chondrosarcoma and integrated this with 90 bulk RNA-seq datasets. This approach enabled detailed characterization of TMM at single-cell resolution, identification of ALT-specific signatures, and evaluation of the tumor microenvironment in chondrosarcomas. Patients with ALT-like chondrosarcomas exhibited significantly improved survival compared to those with non-ALT-like chondrosarcomas. Analysis of the tumor immune microenvironment revealed distinct metabolic and immune landscapes between the ALT-like and non-ALT-like groups. Single-cell analysis showed that high-entropy stem-like cells in high-grade chondrosarcomas predominantly adopted telomerase activation over the ALT pathway as their TMM. Additionally, we identified a 100-gene signature that reliably distinguishes ALT-like chondrosarcomas, providing a robust molecular marker for classification and prognosis. Our study reveals ALT-like state as a marker of favorable prognosis in chondrosarcomas—contrasting with its typically adverse implications in other sarcomas. We establish a robust 100-gene signature that reliably identifies ALT-like chondrosarcomas and characterize their distinct immune microenvironment profile.Keywords
Funding Information
- National Research Foundation of Korea (RS-2023-00213119, RS-2024-00440273, RS-2025-00517430)
This publication has 27 references indexed in Scilit:
- Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT)International Journal of Molecular Sciences, 2018
- Systematic analysis of telomere length and somatic alterations in 31 cancer typesNature Genetics, 2017
- De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome DataCell Stem Cell, 2016
- Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesGenome Medicine, 2016
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitorsScience, 2015
- Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in CancerCell, 2012
- Alternative lengthening of telomeres: models, mechanisms and implicationsNature Reviews Genetics, 2010
- Alternative lengthening of telomeres and survival in patients with glioblastoma multiformeThe Lancet, 2003
- Chondrosarcoma is not characterized by detectable telomerase activityThe Journal of Pathology, 2000
- The Hallmarks of CancerCell, 2000